Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation.

Oncogenic Ras signalling occurs frequently in many human cancers. However, no effective targeted therapies are currently available to treat patients suffering from Ras-driven tumours. Therefore, it is imperative to identify downstream effectors of Ras signalling that potentially represent promising new therapeutic options. Particularly, considering that autophagy inhibition can impair the survival of Ras-transformed cells in tissue culture and mouse models, an understanding of factors regulating the balance between autophagy and apoptosis in Ras-transformed human cells is needed. Here, we report critical roles of the STK38 protein kinase in oncogenic Ras transformation. STK38 knockdown impaired anoikis resistance, anchorage-independent soft agar growth, and in vivo xenograft growth of Ras-transformed human cells. Mechanistically, STK38 supports Ras-driven transformation through promoting detachment-induced autophagy. Even more importantly, upon cell detachment STK38 is required to sustain the removal of damaged mitochondria by mitophagy, a selective autophagic process, to prevent excessive mitochondrial reactive oxygen species production that can negatively affect cancer cell survival. Significantly, knockdown of PINK1 or Parkin, two positive regulators of mitophagy, also impaired anoikis resistance and anchorage-independent growth of Ras-transformed human cells, while knockdown of USP30, a negative regulator of PINK1/Parkin-mediated mitophagy, restored anchorage-independent growth of STK38-depleted Ras-transformed human cells. Therefore, our findings collectively reveal novel molecular players that determine whether Ras-transformed human cells die or survive upon cell detachment, which potentially could be exploited for the development of novel strategies to target Ras-transformed cells

Vitamin D as an Adjunctive Therapy in Asthma. Part 1: A Review of Potential Mechanisms

Vitamin D deficiency (VDD) is highly prevalent worldwide. The classical role for vitamin D is to regulate calcium absorption form the gastrointestinal tract and influence bone health. Recently vitamin D receptors and vitamin D metabolic enzymes have been discovered in numerous sites systemically supporting diverse extra-skeletal roles of vitamin D, for example in asthmatic disease. Further, VDD and asthma share several common risk factors including high latitude, winter season, industrialization, poor diet, obesity, and dark skin pigmentation. Vitamin D has been demonstrated to possess potent immunomodulatory effects, including effects on T cells and B cells as well as increasing production of antimicrobial peptides (e.g. cathelicidin). This immunomodulation may lead to asthma specific clinical benefits in terms of decreased bacterial/viral infections, altered airway smooth muscle-remodeling and efunction as well as modulation of response to standard anti-asthma therapy (e.g. glucocorticoids and immunotherapy). Thus, vitamin D and its deficiency have a number of biological effects that are potentially important in altering the course of disease pathogenesis and severity in asthma. The purpose of this first of a two-part review is to review potential mechanisms whereby altering vitamin D status may influence asthmatic disease

La kinase NDR1, un nouvel acteur de la signalisation des RalGTases, fonctionne comme pivot entre la survie et la mort des cellules cancéreuses

Des mutations du gène Ras jouent un rôle essentiel dans le développement tumoral. Les GTPases Ral , RalA et RalB, sont des effecteurs proximaux de l’oncogène Ras. RalA permet la croissance en absence de substrat et RalB est nécessaire à l'autophagie et à la résistance à l'apoptose des cellules cancéreuses. Cette thèse a pour objectif de clarifier les mécanismes moléculaires de la signalisation Ral impliqués dans l’oncogenèse dépendante des protéines Ras.Des criblages par double hydride ont été effectués par notre équipe et un interactome de Ral a été établi. Ce criblage a montré une interaction entre des protéines de la signalisation Ral et la protéine NDR1, une kinase pro-apoptotique appartenant à la voie " suppresseur de tumeur" Hippo. Le Projet 1 montre la régulation de NDR1 par la voie RalA-Exocyste- MAP4K4 en réponse au stress osmotique, oxydatif ou au traitement par le TNF-α. Dans cette voie, la kinase MAP4K4, un effecteur de RalA, via le complexe exocyste active directement NDR1. En outre, nous avons montré que la voie RalA-MAP4K4-NDR1 était nécessaire à l'apoptose déclenchée par le TNF-α ou par la surexpression de RASSF1A, suppresseur de tumeur appartenant à la voie Hippo. Nous avons donc montré que RalA a un rôle pro-apoptotique inattendue qui agit via la kinase NDR1, en plus de son rôle connu de proto-oncogène en aval de Ras.Le projet 2 montre que la protéine kinase NDR1 est un régulateur de l'autophagie. Des criblages par double hydride ont été effectués par notre équipe avec NDR1 comme appât et ont permis de montrer une interaction entre Beclin 1, une protéine majeure de l’autophagie, et NDR1. Nous avons montré que NDR1 était nécessaire à l'autophagie et à la formation des autophagosomes chez l'humain et la Drosophile. De plus, NDR1 est nécessaire à la formation du complexe Exo84 de l'exocyste, Beclin1 et RalB nécessaire à l'initiation de l'autophagie. Nous montrons également que RalB régule l'état d'activation de NDR 1 après induction de l'autophagie. En effet, en absence de RalB, nous avons observé une hyper - activation de NDR1 menant les cellules vers l'apoptose. Ainsi nous avons montré que NDR1 joue le rôle d'interrupteur favorisant l'autophagie ou favorisant l'apoptose suivant son état d'activation.Le projet 3 étudie l'implication de la voie RalGTPases-NDR1 dans l'oncogenèse dépendante de Ras et dissèque par quels mécanismes NDR1 y contribue.Constitutive Ras signalling is one of the most frequent oncogenic event in human cancers. Thus, it is imperative to identify new therapeutic options targeting downstream effectors of Ras signalling. Ras-like GTPases RalA and RalB are proximal effectors of oncogenic Ras. RalA was reported to support anchorage independent proliferation and RalB regulates autophagy and inhibits apoptosis of cancer cells. Ral proteins execute these functions via several direct effectors as the exocyst, an octameric complex originally identified as regulator of vesicles trafficking. The global goal of this PhD was to better decipher the molecular mechanisms underlying the functions of Ral GTPases in oncogenesis.To extend the Ral interactome, i.e. the protein-protein interaction network centered on Ral, we performed yeast-two hybrid screenings which led to the identification of the NDR1 kinase, belonging to the tumor suppressor Hippo pathway. NDR1 functions in oncogenesis were investigated in the context of three projects.In Project 1, we showed that NDR1-dependent apoptosis is regulated by a RalA/Exocyst/MAP4K4/NDR1 cascade. We reported that under osmotic or oxidative stresses or TNF-α treatment, the Ste20-like MAP4K4 kinase, an effector of RalA via the exocyst complex, directly activates NDR1. Moreover, we found that TNF-α treatment or overexpression of the tumor suppressor RASSF1A, which belongs to the Hippo pathway, leads to apoptosis through this RalA/Exocyst/MAP4K4/NDR1 pathway. This novel and unexpected pro-apoptotic role of RalA suggests that the RalA GTPase can positively signal in tumor suppressor pathways via the kinase NDR1, in addition to its proto-oncogenic role downstream of Ras. In Project 2, we described the NDR1 protein kinase as a conserved regulator of autophagy. Using NDR1 as bait in yeast two hybrid screens, we fished Beclin1, a key regulator of autophagy, and we validated the existence of a direct biochemical NDR1-Beclin1 interaction. We showed that NDR1promotes autophagosome formation in human cells and Drosophila larvae. Furthermore, we observed that NDR1 supports the interaction of the exocyst component Exo84 with Beclin1 and RalB, which is required to initiate autophagosome formation. Very interestingly, under prolonged autophagy, RalB depletion triggers hyperactivation of NDR1 resulting in NDR1-dependent apoptosis. Thus, it appears that the NDR1 kinase could act as a switch between autophagy (=survival) or apoptosis (=death), under the control of RalB. In Project 3, we addressed the role of the newly identified RalGTPases-NDR1axis in Ras - induced oncogenesis and tumorigenesis

Studies on the transcriptional regulation and differential splicing of the human parathyroid hormone (PTH)PTH-related peptide (PTHRP) receptor gene (PTHR)

Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) stimulate signal transduction in target cells by binding to the same G protein-linked receptor (PTHR). The PTHR mediates PTH signaling in kidney and bone, and PTHrP binding to the receptor has been shown to be essential for normal endochondral bone formation in humans and mice.Expression of the murine PTHR gene is controlled by two promoters that are regulated differently. Whereas the activity of the upstream promoter (P1) is mainly restricted to the kidney, where it provides the bulk of the gene transcription, the downstream promoter (P2) is more widely active. We characterized the upstream regulatory region of the human PTHR gene and showed that its organization is very similar to that of the mouse PTHR gene. RNase protection experiments revealed, however, that the homologue of the mouse renal-specific promoter PI, is only weakly active. This observation led us to identify and characterize a third promoter P3) that is responsible for the expression of more than 80% of human renal transcripts, but is apparently not active in mouse kidney. A study of the tissue distribution of the activity of P1, P2 and P3 showed that, while P2 and P3 are widely active, function of P1 is restricted to renal tissues. This study further revealed the existence of a shorter, differentially spliced variant of P2 derived transcripts. P1 and P3 were found to be developmentally regulated, as no activity was detected at mid-gestation. Hence, expression of the PTHR gene until this stage is driven solely by P2. Furthermore, the shorter P2-specific transcript observed in adult not detected in fetal tissues, suggesting that differential splicing of PTHR mRNA is developmentally regulated as well.The observation that activity of PI and P3 is developmentally up-regulated, and the presence of P3 within a CpG island, prompted us to examine whether DNA methylation could play a role in regulating PTHR promoter function. Our results show that all three promoters are sensitive to methylation in vitro and that the methylation pattern of Pl is renal specific and is established well before the onset of PTHR gene expression. Our results suggest that while the transcriptional regulation of the PTIHR gene expression during development might be similar in mouse and human, expression in the adult is likely to be controlled by different mechanisms.We also addressed the presence of structural alterations of the 5 ' regulatory region in patients with pseudohypoparathyroidism type Ib. Genomic southern blot analysis, as well as sequencing of the three upstream untranslated exons did not reveal any deletion or point mutation that could account for the kidney specific loss of PTH response observed in these patients

Une perspective pour l’Europe du nucléaire à l’horizon 2030

Cet article dresse un panorama des évolutions du mix électrique à horizon 2030 pour l'Europe des 27 et analyse plus en détail la place du nucléaire – actuellement 140 GW installés - vue significativement plus importante que ce qu'envisage la Commission Européenne. Au total, on devrait voir sur la période à venir des augmentations de puissance à hauteur de 6000 MW ; une extension de durée de fonctionnement de nombreuses centrales de + 15 ans en moyenne ; des constructions neuves (y compris celles déjà lancées) à hauteur de + 70 GW. Cet ensemble de mesures permettrait de maintenir la part du nucléaire à environ 30 % de la consommation électrique

The pro-apoptotic STK38 kinase is a new Beclin1 Partner positively regulating autophagy

SummaryAutophagy plays key roles in development, oncogenesis, cardiovascular, metabolic, and neurodegenerative diseases. Hence, understanding how autophagy is regulated can reveal opportunities to modify autophagy in a disease-relevant manner. Ideally, one would want to functionally define autophagy regulators whose enzymatic activity can potentially be modulated. Here, we describe the STK38 protein kinase (also termed NDR1) as a conserved regulator of autophagy. Using STK38 as bait in yeast-two-hybrid screens, we discovered STK38 as a novel binding partner of Beclin1, a key regulator of autophagy. By combining molecular, cell biological, and genetic approaches, we show that STK38 promotes autophagosome formation in human cells and in Drosophila. Upon autophagy induction, STK38-depleted cells display impaired LC3B-II conversion; reduced ATG14L, ATG12, and WIPI-1 puncta formation; and significantly decreased Vps34 activity, as judged by PI3P formation. Furthermore, we observed that STK38 supports the interaction of the exocyst component Exo84 with Beclin1 and RalB, which is required to initiate autophagosome formation. Upon studying the activation of STK38 during autophagy induction, we found that STK38 is stimulated in a MOB1- and exocyst-dependent manner. In contrast, RalB depletion triggers hyperactivation of STK38, resulting in STK38-dependent apoptosis under prolonged autophagy conditions. Together, our data establish STK38 as a conserved regulator of autophagy in human cells and flies. We also provide evidence demonstrating that STK38 and RalB assist the coordination between autophagic and apoptotic events upon autophagy induction, hence further proposing a role for STK38 in determining cellular fate in response to autophagic conditions